Recombinant Activated Factor VII (rFVIIa) as a Hemostatic Agent in Liver Disease: A Break from Convention in Need of Controlled Trials

Keyphrases

• Coagulopathy 100%
• Liver Disease 100%
• Recombinant Activated Factor VII (rFVIIa) 100%
• Hemostatic Agents 100%
• Renal Failure 50%
• Infection Risk 50%
• Healthcare Professionals 50%
• Clinical Application 50%
• Mechanism of Action 50%
• Platelets 50%
• Chronic Liver Disease 50%
• Portal Hypertension 50%
• Endothelial Dysfunction 50%
• Clinical Situation 50%
• Cost-effectiveness 50%
• Transfusion Reaction 50%
• Laboratory Indexes 50%
• Coagulation 50%
• Vitamin K 50%
• Disseminated Intravascular Coagulation 50%
• Associated Risk 50%
• Clotting Cascade 50%
• Transfusion Risks 50%
• Volume Expansion 50%
• Clotting Factors 50%
• Patients with Liver Disease 50%
• Overexpansion 50%
• Acute Liver Disease 50%
• Despair 50%
• Hyperfibrinolysis 50%
• Synthetic Function 50%
• Hypofibrinogenemia 50%

Medicine and Dentistry

• Factor VII 100%
• Liver Disease 100%
• Hemostat 100%
• Coagulopathy 66%
• Blood Clotting Factor 66%
• Renal Failure 33%
• Health Care Provider 33%
• Clinician 33%
• Infection 33%
• Platelet 33%
• Chronic Liver Disease 33%
• Portal Hypertension 33%
• Cost-Effectiveness Analysis 33%
• Blood Transfusion Reaction 33%
• Endothelial Dysfunction 33%
• Disseminated Intravascular Coagulation 33%
• Hyperfibrinolysis 33%
• Dysfibrinogenemia 33%
• Hopelessness 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Disease 100%
• Hemostatic Agent 100%
• Blood Clotting Factor 7 100%
• Blood Clotting Disorder 66%
• Blood Clotting Factor 66%
• Kidney Failure 33%
• Infection 33%
• Chronic Liver Disease 33%
• Endothelial Dysfunction 33%
• Blood Transfusion Reaction 33%
• Disseminated Intravascular Clotting 33%
• Vitamin K Group 33%
• Portal Hypertension 33%
• Dysfibrinogenemia 33%